April 2026 Research Update

Studies this month added a broader picture of fenfluramine in Dravet syndrome: families reported day-to-day gains that did not always match seizure changes, and an expert group outlined how heart monitoring can be organized around treatment. Put together, this month strengthens the idea that the fenfluramine conversation is often about more than seizure counts, while also keeping safety follow-up in view. The evidence is still limited, but it gives a clearer sense of what families notice and what monitoring plans may look like. [1] [2]

In a small clinic sample of 21 people on long-term add-on fenfluramine, caregivers most often described improvements in expressive language, attention, alertness, and behavior regulation over the prior 12 months, even though cognitive impairment was severe and seizure control varied. About half had at least a 50% seizure reduction, and some were seizure-free, but the reported functional changes were not presented as depending on becoming seizure-free. Younger age and more frequent rehabilitation were linked to larger caregiver-reported gains, while earlier seizure onset was linked to poorer outcomes in this dataset. [1]

A separate paper did not report new patient outcomes, but presented an expert-developed cardiology follow-up pathway for people with Dravet syndrome treated with fenfluramine. The purpose was to support prevention and early detection of possible cardiovascular events by organizing checks before, during, and after treatment. This adds structure to how some teams may coordinate neurology and cardiology follow-up around this medication. [2]

For families already familiar with fenfluramine, this month adds two practical pieces of understanding: some caregivers report changes in communication, attention, and behavior that can be meaningful in daily life, and experts are working on clearer safety follow-up routines. The caregiver-report study is small and cannot prove that fenfluramine caused the changes, but it helps clarify the kinds of improvements families are watching for in addition to seizures. The monitoring paper is expert consensus rather than a trial result, so it mainly matters as a way to describe how follow-up may be organized rather than as proof of benefit. [1] [2]

This month included research focused on the caregiver side of Dravet syndrome, and the message was clear: day-to-day challenges were linked to higher parent distress, while feeling more empowered was linked to less distress. Rather than pointing to a single problem, the study described a cluster of pressures that families commonly face, including unpredictable behavior and navigating systems. It also showed that measurable aspects of the childs behavior relate to how distressed parents feel. [3]

Across focus groups and questionnaires, parents described managing unpredictable child behavior, protecting their own mental health, adjusting work and family life, and working through the healthcare system. In the questionnaire portion, higher parent empowerment scores went along with lower distress scores, and more child behavioral difficulties went along with higher parent distress. This connects lived experience with measurable patterns and helps show how important behavioral and support needs can be in daily family life. [3]

This research does not test a treatment, but it adds evidence that caregiver well-being is closely tied to a childs behavior and to how supported and capable parents feel in managing the condition. It may matter now mainly as validation and as a research foundation for future support programs, because it identifies factors linked to distress without proving what reduces it. What remains uncertain is whether boosting empowerment directly lowers distress, since the study measured relationships at a point in time rather than testing an intervention. [3]

Several studies this month tried to explain why Dravet syndrome and related epilepsies can look so different from one person to another, using genetics and early-stage biology models. The common pattern was early signals rather than clinical answers: gene findings and inflammation markers tracked with more severe epilepsy in broader pediatric groups, and lab models showed measurable brain or cell differences linked to seizure susceptibility or severity. These studies mainly build the long-term goal of better ways to classify risk and understand mechanisms, not immediate changes in care. [4] [5] [6] [7]

In a single-center study of 61 children with fever-sensitive epilepsy who had genetic testing, gene-positive children tended to have earlier seizure onset, more episodes of status epilepticus, and more developmental delay after onset than gene-negative children. SCN1A was the most common gene finding, and 11 children were ultimately diagnosed with Dravet syndrome. The study also reported differences between gene-positive children whose treatments were considered effective versus ineffective, but the summary did not describe which specific medications worked better. [4]

Inflammation was linked with more severe epilepsy in a study combining patient data and animal work, suggesting that immune signals may be part of the bigger picture in drug-resistant epilepsy that includes Dravet syndrome. In a pediatric cohort, blood markers of inflammation (including CRP) were higher in drug-resistant epilepsy than in a comparison epilepsy group, and CRP was reported as independently linked with progression to drug resistance. In mice with an Scn1a change, a STAT3-related inflammation signal was highlighted in brain tissue and tracked closely with peripheral inflammation measures. [5]

Two lab studies focused on measuring brain-related differences that might underlie seizure risk and symptom severity. In zebrafish with a Dravet-related gene change, brain-wide imaging showed different network activity patterns during induced seizures, and even baseline patterns helped identify the mutant fish and predict seizure risk in that model. In a separate study using urine-derived cells from 3 people with Dravet syndrome, patient-derived early brain-cell clusters showed different protein patterns that lined up with differences in clinical severity, highlighting that Dravet biology may vary substantially across individuals even when SCN1A is involved. [7] [6]

For families, these studies mainly add explanation rather than new actions: they support that genetics often relates to how early and how severe fever-sensitive epilepsy can be, and they point to inflammation and brain-network differences as possible contributors to drug resistance and symptom severity. The inflammation and lab-model findings are early-stage and do not show that changing inflammation or a specific pathway will improve outcomes in people. What became clearer this month is that researchers are aligning clues across blood tests, brain tissue signals in animals, and patient-derived cell models to understand why Dravet syndrome varies so much person to person. [4] [5] [6] [7]

A small genetic report this month described another form of early-onset epilepsy with developmental and autism-related features. The key contribution was identifying a new SCN1B splice-site variant shared by four affected people from two families. Because this was only a few people in two families, it mainly adds to genetic knowledge rather than changing what is known for most families. [8]

In two unrelated consanguineous families, all affected individuals had early seizures along with developmental delay, intellectual disability, and autism spectrum disorder, and genetic testing found the same novel homozygous SCN1B splice-site variant. The authors interpreted this shared variant as the likely cause in these families. This kind of report helps connect specific gene findings to a recognizable set of challenges, even though it cannot predict outcomes for others with different backgrounds or variants. [8]

This report may matter most for families navigating genetic answers, because it shows that genes beyond SCN1A, such as SCN1B, can be linked to severe early epilepsy plus developmental and autism-related needs. It is mainly research knowledge right now, since it comes from only 4 affected people and does not test a treatment. What remains uncertain is how often this variant occurs in other populations and whether people with other SCN1B variants have similar courses. [8]